Gender as a clinically relevant outcome variable in acne: Benefits of a fixed combination clindamycin phosphate (1.2%) and benzoyl peroxide (2.5%) aqueous gel

Journal of Drugs in Dermatology

Volumn 11, Issue 12, 2012, Pages 1440-1445

  Harper, Julie C ^a  

^a Dermatology and Skin Care Center of Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZOYL PEROXIDE PLUS CLINDAMYCIN;

ACNE; ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL EXAMINATION; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; OUTCOME ASSESSMENT; POST HOC ANALYSIS; SCHOOL CHILD; SEX DIFFERENCE;

ACNE VULGARIS; ADOLESCENT; ADULT; ANTI-BACTERIAL AGENTS; BENZOYL PEROXIDE; CLINDAMYCIN; DIAGNOSTIC SELF EVALUATION; DRUG COMBINATIONS; ERYTHEMA; ETHNIC GROUPS; FEMALE; GELS; HUMANS; KERATOLYTIC AGENTS; MALE; SEX CHARACTERISTICS; SKIN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84871070262     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Dao H Jr, Kazin RA. Gender differences in skin: a review of the literature. Gend Med. 2007;4(4):308-328.
2. Chen W, Mempel M, Traidl-Hofmann C, Al Khusaei S, Ring J. Gender aspects in skin disease. J Eur Acad Dermatol Venereol. 2010; 24(12):1378-1385.
3. Heymann WR. Oral contraceptives for the treatment of acne vulgaris. J Am Acad Dermatol. 2007;56(6):1056-1057. (Pubitemid 46729697)
4. Shaw JC. Acne: effect of hormones on pathogenesis and management. Am J Clin Dermatol. 2002;3(8):571-578, (Pubitemid 35252507)
5. Berg M, Lindberg M. Possible gender differences in the quality of life and choice of therapy in acne. J Eur Acad Dermatol Venereol. 2011;25(8):969-972.
6. Stern RS. The prevalence of acne on the basis of physical examination. J Am Acad Dermatol. 1992;26(6):931-935.
7. Chuan SS, Chang RJ. Polycystic ovary syndrome and acne. Skin Ther Lett. 2010;15(10):1-4.
8. Harper J, Oefelein M, Tanghetti EA. The effifcacy and tolerability of dapsone 5% gel in female versus male patients with facial acne vulgaris: gender as a clinically relevant outcome variable. Poster presented at: 29th Fall Clinical Dermatology Conference 2010, Las Vegas, NV, October 8-11, 2010.
9. Choi CW, Lee DH, Kim HS, Kim BY, Park KC, Youn SW. The clinical features of late onset acne compared with early onset acne in women. J Eur Acad Dermatol Venereol. 2011;25(4):454-461.
10. Thiboutot D, Zaenglein A, Weiss J, Webster G, Calvarese B, Chen D. An aqueous gel fixed combination of clindamycin phosphate 1.2% and benzoyl peroxide 2.5% for the once-daily treatment of moderate to severe acne vulgaris: assessment of efficacy and safety in 2813 patients. J Am Acad Dermatol. 2008;59(5):792-800.
11. Bikowski J. Rediscovering topical antimicrobial therapy for acne vulgaris. Pract Dermatol. 2009;55-58.
12. Gold MH. A new, once-daily, optimized, fixed combination of clindamycin phosphate 1.2% and low-concentration benzoyl peroxide 2.5% gel for the treatment of moderate-to-severe acne. J Clin Aesthet Dermatol. 2009;2(5):44-48.
13. Cook-Bolden F. Clindamycin phosphate 1.2% and benzoyl peroxide 2.5%: a new, once-daily, fixed combination treatment for moderate to severe acne. Cosmet Dermatol. 2009;22(6):319-322.
14. Webster G, Rich P, Gold MH, Mraz S, Calvarese B, Chen D. Efficacy and tolerability of a fixed combination of clindamycin phosphate (1.2%) and low concentration benzoyl peroxide (2.5%) aqueous gel in moderate or severe acne subpopulations. J Drugs Dermatol. 2009;8(8):736-743.
15. Recent developments: Novel fixed-combination clindamycin phosphate and low-concentration benzoyl peroxide formulation shows effifcacy, tolerability. Pract Dermatol Pediatr. 2010;6-7. http://bmctoday.net/practicaldermatology-peds/ 2010/08/article.asp?f=recent-developments.
16. Del Rosso JQ. Topical management of acne vulgaris using a combination gel formulation: benzoyl peroxide 2.5%-clindamycin phosphate 1.2% gel. Expert Rev Dermatol. 2010;5(6):597-603.